Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. reported a net loss of $8.7 million for fiscal year 2025, compared to a net loss of $7.2 million in 2024. The company generated no product revenue and incurred total operating expenses of $9.2 million, primarily from research and development ($4.6 million) and general and administrative costs ($4.6 million). Cash and cash equivalents increased significantly to $21.0 million at year-end 2025 from $5.4 million in 2024, driven by $23.6 million in net cash provided by financing activities from warrant exercises and stock issuances. The company remains a clinical-stage biopharmaceutical company with its lead candidate PH-762 in Phase 1b trials, and management believes current cash resources are sufficient for at least 12 months of operations.

Key Takeaways